MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
6.96
+0.08 (1.16%)
Nov 21, 2024, 1:43 PM EST - Market open
MannKind Revenue
MannKind had revenue of $70.08M in the quarter ending September 30, 2024, with 36.73% growth. This brings the company's revenue in the last twelve months to $267.20M, up 51.35% year-over-year. In the year 2023, MannKind had annual revenue of $198.96M with 99.42% growth.
Revenue (ttm)
$267.20M
Revenue Growth
+51.35%
P/S Ratio
7.00
Revenue / Employee
$645,411
Employees
414
Market Cap
1.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.53B |
National HealthCare | 1.22B |
Evotec SE | 866.67M |
Tandem Diabetes Care | 854.35M |
Harmony Biosciences Holdings | 681.88M |
Azenta | 656.32M |
Supernus Pharmaceuticals | 651.97M |
NeoGenomics | 644.12M |
MNKD News
- 13 days ago - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - MannKind to Present at 2024 UBS Healthcare Conference - GlobeNewsWire
- 17 days ago - MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases - GlobeNewsWire
- 20 days ago - MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 - GlobeNewsWire
- 21 days ago - First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - GlobeNewsWire
- 7 weeks ago - MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion - Seeking Alpha
- 7 weeks ago - More Adults With Type 1 Diabetes Achieved A1C Goal ( - GlobeNewsWire